NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain

CompletedN/A

Sponsor: AstraZeneca

Conditions: Asthma

Countries: Spain

Observational retrospective study to characterize and assess clinical outcomes of patients receiving tezepelumab after marketing approval in Spain

Eligibility overview

Sex: ALL

Age: 12 Years to 105 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

Patients who received at least 1 tezepelumab dose after commercialization in Spain diagnosed with severe asthma who are inadequately controlled with high-dose inhaled corticosteroids and a long-acting β2-agonist ± additional medications for asthma control.

* Patients aged ≥12 years at the index date.
* Patients with continuous enrolment in the data source for at least 12-months before the index date.
* Patients with at least three months of continuous enrolment in the data source after the index date.

Exclusion Criteria:

Patients who received tezepelumab or any biologic drug for the treatment of asthma in a clinical trial at any time during the 12-months prior to the index date\*.

• Patients who had initiated 3 or more non-tezepelumab biologic treatment (omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab) for severe asthma at any time prior to the index date).

Locations (12)

Andalucia, Spain
C. Valenciana, Spain
C. Y Leon, Spain
Cantabria, Spain
Castilla La Mancha, Spain
Cataluna, Spain
Extremadura, Spain
Galicia, Spain
Islas Canarias, Spain
Madrid, Spain
Navarra, Spain
Pais Vasco, Spain